Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of cabotegravir long-acting PrEP after HPTN 083/HPTN 084
PACTR202404510501536Phase 3Not yet recruiting
- Sponsor
- ViiV Healthcare
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoint: New HIV infections. Planned start May 2024; status: not yet recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202404510501536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202404510501536.